Family Faces Prolonged Uncertainty Over NHS Funding for Life-Saving Drug

The family of a young girl suffering from a rare neurodegenerative condition expresses concern that they may lose her if the National Health Service (NHS) does not secure permanent funding for her ongoing treatment. Gail Rich, from Newcastle, had two daughters, Nicole and Jessica, both diagnosed with the incurable Batten Disease. Nicole passed away in 2023 due to complications associated with the condition. Her nine-year-old sister, Jessica, continues to receive a life-prolonging treatment, Brineura, but the determination regarding its continued availability on the NHS has been postponed for six months. Ms Rich stated, “It’s excruciating having to wait. We’ve got no control. We just have to sit and wait to see whether or not our children will have a future.” The National Institute for Health and Care Excellence (NICE) issued a statement indicating that discussions between NHS England and the pharmaceutical company BioMarin have been “constructive” to date. Jessica undergoes a brain infusion every two weeks at Newcastle’s Royal Victoria Infirmary, a procedure designed to decelerate the disease’s progression. According to Ms Rich, her daughter’s active lifestyle, including her enjoyment of school and dancing, serves as evidence of the treatment’s efficacy. Brineura has been accessible to eligible NHS patients since 2019 through a managed access agreement. However, Ms Rich expressed concern that the treatment might be discontinued, asserting that its absence would lead to a rapid deterioration in her daughter’s condition. She further stated, “It’s not the effectiveness of the treatment that’s now being decided upon, because everyone agrees it works. It’s how much they are willing to pay.” Ms Rich added, “It’s all coming down to money now. Our daughter’s life depends upon a financial agreement being reached. That’s really hard to understand…what’s the price of a life?” A final decision regarding the drug’s permanent availability is now anticipated by the end of May 2025. Liz Brownnutt of the Batten Disease Family Association highlighted that families now face six months of uncertainty. She commented, “Their time is precious with their children and they shouldn’t have to be worried about whether or not their children are going to get this treatment in the future.” NICE confirmed, “All parties will now use the extension period to try to reach an agreement that secures permanent access for current patients and allows new patients to start treatment.”